An amendment to Schedule 13G has been filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a change in their holdings of ZyVersa Therapeutics, Inc. common stock. The filing, dated September 30, 2024, reports that these entities and individuals collectively own 54,054 shares, representing 4.9% of the company's issued common stock. This stake is held by a private fund for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors, with the power to direct voting and disposition of the shares. The amendment restates the previously filed Schedule 13G and provides updated information on the beneficial ownership, including the address and organizational details of the reporting persons. The filing also certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.

An amendment to Schedule 13G has been filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a change in their holdings of ZyVersa Therapeutics, Inc. common stock. The filing, dated September 30, 2024, reports that these entities and individuals collectively own 54,054 shares, representing 4.9% of the company's issued common stock. This stake is held by a private fund for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors, with the power to direct voting and disposition of the shares. The amendment restates the previously filed Schedule 13G and provides updated information on the beneficial ownership, including the address and organizational details of the reporting persons. The filing also certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.